Boston Scientific’s Strategic Shift and Resilient Outlook: A Buy Rating with 17.7% Expected Return

Analyst Joanne Wuensch from Citi maintained a Buy rating on Boston Scientific (BSX – Research Report) and keeping the price target at $125.00.

Joanne Wuensch’s rating is based on Boston Scientific’s strategic decision to discontinue its global sales of TAVR valves, which reflects a prudent approach to resource management. Despite the challenges faced in obtaining regulatory approvals in the U.S. and other regions, the company has managed to maintain its sales and earnings guidance for the upcoming quarters.
Furthermore, the company’s ability to navigate regulatory hurdles and still project a positive financial outlook demonstrates strong management and operational resilience. Wuensch’s Buy rating is supported by the expected share price return of 17.7%, indicating confidence in the company’s future performance and growth potential.

According to TipRanks, Wuensch is a 5-star analyst with an average return of 7.4% and a 64.60% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as Abbott Laboratories, Dexcom, and Cooper Co.

In another report released today, Needham also maintained a Buy rating on the stock with a $115.00 price target.